To confirm these effects, we performed the correlation between tumoral ABHD17C and the efficacy of anti-PD1 therapy (Fig. 7a, b); We first searched for datasets of pancreatic cancer patients treated with Anti-PD1/CTLA-4/PD-L1. This evidence concerns the gene CTLA4 and familial pancreatic carcinoma.